AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02851485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral solution fasted
Description: dosing after overnight fasting
Study NCT02851485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral tablet fasted
Description: dosing after overnight fasting
Study NCT02851485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral tablet fed
Description: dosing after high-fat high-calorie breakfast
Study NCT02216045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon, Ribavirin, camel milk
Description: Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks.
Study NCT02216045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon, Ribavirin
Description: Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks.
Study NCT04040504 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
Description: ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.
Study NCT04040504 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP procedure with Pentax ED-34i10T Duodenoscope
Description: ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
Study NCT01258413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy
Description: uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
Study NCT01258413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radical hysterectomy
Description: uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
Study NCT00329511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyldopa vs. clonidine
Description: Comparison of compliance
Study NCT00329511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine patch
Description: methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discovery Vitality base program
Description: The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discovery Vitality base program
Description: The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication
Description: Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Charitable Incentive
Description: Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize Draw Incentive
Description: Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Payment
Description: Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
Study NCT01277367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Free Choice
Description: Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
Study NCT02561065 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.
Study NCT01129466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement A followed by Supplement B
Description: Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
Study NCT01129466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement B followed by Supplement A
Description: Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
Study NCT02269332 — intervention group
Intervention type: OTHER
Intervention: Screening Colonoscopy
Description: we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
Study NCT04565379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.1 mg
Description: NuSepin® 0.1 mg
Study NCT04565379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.2 mg
Description: NuSepin® 0.2 mg
Study NCT04565379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT00226837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide
Description: nitrous oxide by inhalation during induction
Study NCT00226837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: nitrous oxide by inhalation during induction
Study NCT03451617 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent delivery with Xpedition
Description: Use of Xpedition stent delivery system to implant the XIENCE stent
Study NCT03451617 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent delivery with Alpine
Description: Use of Alpine stent delivery system to implant the XIENCE stent
Study NCT03735212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Services
Description: Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
Study NCT03824639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: Exercise instruction and encouragement
Study NCT03824639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Provision of general information about a variety of health topics
Study NCT01457989 — intervention group
Intervention type: DRUG
Intervention: retigabine/ezogabine
Description: dose range up to 1200 mg/day
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MeDALL questionnaire for allergic diseases
Description: Questionnaire about allergic symptoms and disease
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Registration of allergic symptoms
Description: Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Prick Test
Description: Diagnostic skin test for sensitization to allergens
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Specific IgE in serum
Description: Diagnostic test for sensitization to allergens in serum
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal provocation test
Description: Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)
Study NCT04322838 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Basophil Activation Test
Description: Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
Study NCT01195051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic medication reconciliation
Description: A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
Study NCT02041234 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Description: Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
Study NCT02041234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretin analogues
Description: Incretin analogues: Liraglutide up to 1.8 mg daily
Study NCT02041234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical
Description: Xenical: Up to 120 mg tds
Study NCT02041234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitors
Description: SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
Study NCT02041234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 Inhibitors
Description: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
Study NCT02359682 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study NCT02628782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeal's Vascular Closure Device
Description: Intravascular closure device
Study NCT03594604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.
Study NCT03594604 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pill
Description: Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
Study NCT04557943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th.
Study NCT04557943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
Study NCT02649946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covera Vascular Covered Stent following PTA
Description: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.
Study NCT02649946 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
Description: Treatment of stenoses with PTA only
Study NCT03687047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New complete dentures
Description: Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
Study NCT03655821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Dosing is either based on BSA or renal function
Study NCT03655821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dosing is either based on BSA or renal function
Study NCT03012607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
Study NCT01047293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells.
Study NCT01047293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
Study NCT01047293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
Study NCT01045395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch
Description: 90mg/d
Study NCT01045395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unique Marine Algae Concentrate (UMAC)
Description: 90mg/d
Study NCT01045395 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Golden brown algae
Description: 90mg/d
Study NCT01209780 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Investigational egg-derived trivalent subunit influenza vaccine.
Study NCT01209780 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVf
Description: US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
Study NCT01209780 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator TIV
Description: US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
Study NCT04510831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined maize with extrinsic addition of labelled FeSO4
Description: Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)
Study NCT04510831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T.molitor native chitin
Description: Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
Study NCT04510831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T molitor reduced chitin
Description: Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
Study NCT02325427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS could deliver either real or sham stimulation.
Study NCT02325427 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS could deliver either real or sham stimulation.
Study NCT04280068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Guide (CG)
Description: An evidence-based, intervention approach to reduce heavy drinking in primary care settings.
Study NCT04280068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Guide plus HealthCall
Description: HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
Study NCT00679627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
Study NCT00679627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT00757783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: 100 mg capsule or tablet once daily for 48 weeks
Study NCT00757783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: 800 mg tablet once daily for 48 weeks
Study NCT00757783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine [FTC]/tenofovir [TDF]
Description: 200/300 mg tablet once daily for 48 weeks
Study NCT00757783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine [FTC]/tenofovir [TDF]
Description: 200/300 mg once daily for 48 weeks
Study NCT00757783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atazanavir
Description: 300 mg capsule once daily for 48 weeks
Study NCT01043393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desoximetasone 0.25% spray
Description: Desoximetasone spray applied to affected areas twice daily for 28 days
Study NCT04234854 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intravascular Utrasound (IVUS) of Carotid Artery after implantation of CGuard stent
Description: IVUS will be performed after stent postdilatation to determine the incidence of plaque prolapse. Additionally optimizing stent expansion with IVUS is left at operator discretion.
Study NCT04176146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer comparison and social norms messaging
Description: This group will receive a letter noting that their organization has not implemented at least one common care delivery practice that a majority their peers have already implemented. The letter will also note the percentage of peer organizations that have implemented the practice. This is done using peer comparison data and social norms messaging.
Study NCT04650308 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuropeptide Y examination
Description: This examination was conducted by drawing blood serum from research subjects and performing centrifugation with 2000-3000 revolutions per minute (RPM) for 20 minutes. Furthermore, we carried out blood serum tests to check neuropeptide Y levels using the Human Neuropeptide Y Enzyme-link Immunosorbent Assay (ELISA) kit